Reply to “COVID vaccine–induced lichen planus on areas previously affected by vitiligo”

Bularca, Elena Aura; Serrano, Juan Monte; Villagrasa-Boli, Pablo; Lapeña-Casado, Alejandro; de‐la‐Fuente‐Meira, S.

doi:10.1111/jdv.18001

Cited by 7 publications

(7 citation statements)

References 14 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A review of the world literature describing COVID-19 vaccine-associated cases of cutaneous lichen planus and lichenoid eruptions is summarized in Table 2 . The search produced twenty-eight articles that discussed 31 cases of COVID-19 vaccine-associated lichenoid eruptions [ 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 ].…”

Section: Resultsmentioning

confidence: 99%

“…The pathology showed lichenoid interface dermatitis with or without dermal eosinophils. Since that time, published case reports [ 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 ] and one small case series [ 63 ] cumulatively report on 29 additional patients. New-onset and reactivation of oral lichen planus has also been reported [ 43 , 64 , 65 ].…”

Section: Resultsmentioning

confidence: 99%

“…An additional three cases (20%) received a subsequent dose of the vaccine (booster dose) and reported no cutaneous reaction at all. Six of the patients (19.4%) from the literature review group reactivated upon rechallenge with the next dose of the vaccine [ 40 , 41 , 42 , 53 , 57 , 58 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

COVID-19 Vaccine-Induced Lichenoid Eruptions—Clinical and Histopathologic Spectrum in a Case Series of Fifteen Patients with Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Lichen planus is a distinctive mucocutaneous disease with well-established clinical and histopathologic criteria. Lichenoid eruptions closely resemble lichen planus and may sometimes be indistinguishable from it. Systemic agents previously associated have included medications, viral infections and vaccines. Sporadic case reports of lichen planus and lichenoid reactions associated with COVID-19 vaccines have recently emerged. Herein, we review the world literature (31 patients) and expand it with a case series of 15 patients who presented with vaccine-induced lichenoid eruption (V-ILE). The spectrum of clinical and histopathologic findings is discussed with emphasis on the subset whose lesions manifested in embryologic fusion lines termed lines of Blaschko. This rare Blaschkoid distribution appeared in seven of the 46 patients studied. Of interest, all seven were linked to the mRNA COVID-19 vaccines. We believe that all lichenoid eruptions should be approached with a heightened index of suspicion and patients should be specifically questioned with regards to their vaccination history. When diagnosed early in its course, V-ILE is easily treated and resolves quickly in almost all patients with or without hyperpigmentation. Additional investigative studies regarding its immunopathology and inflammatory signaling pathways may offer insight into other Th1-driven autoimmune phenomena related to COVID-19 vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 Vaccine-Induced Lichenoid Eruptions—Clinical and Histopathologic Spectrum in a Case Series of Fifteen Patients with Review of the Literature

et al. 2023

View full text Add to dashboard Cite

show abstract

“… COVID-19 Vaccine type Latency (days) Distribution Treatment Outcome 29-y.o. F [ 3 ] (Bularca et al) Vaccination Tozinameran, 2nd dose (Pfizer-BioNTech) 7 days Dorsum of the hands, wrists, eyelids, sub-mammary region, lower extremities, and oral mucosa Methotrexate Unspecified 63-y.o. F [ 4 ] (Paolino and Rongioletti) Vaccination Tozinameran, 2nd dose 3 days Palms, wrists, and soles Acitretin 25 mg/day, topical calcipotriene/betamethasone dipropionate foam Total resolution of lesions in 1 month, but with residual palmar hyperpigmentation 49-y.o.…”

Section: Appendixmentioning

confidence: 99%

Lichen planus after COVID-19 infection and vaccination

Zou

Daveluy

2022

Arch Dermatol Res

View full text Add to dashboard Cite

Lichen planus (LP) is an inflammatory disorder believed to result from CD8 + cytotoxic T -cell (CTL)-mediated autoimmune reactions against basal keratinocytes. We present a review of LP following COVID-19 infection and vaccination. Literature searches were conducted on PubMed and Google Scholar from 2019 to 7/2022. 36 articles were selected based on subject relevance, and references within articles were also screened. 39 cases of post-vaccination LP and 6 cases of post-infection LP were found among case reports and case series. 152 cases of post-vaccination LP and 12 cases of post-infection LP were found in retrospective and prospective studies. LP is a rare complication of COVID-19 infection and vaccination that may be mediated by overstimulation of T -cell responses and proinflammatory cytokine production. However, it does not represent a limitation against COVID-19 vaccination, and the benefits of vaccination considerably outweigh the risks.

show abstract

“…Although there have been no reports of LLP, there are reports of nine patients with lichen planus (LP) after COVID‐19 vaccination. 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 Because LLP is a variant of LP, we reviewed 10 patients including our patient (Table 1 ). Nine of the 10 patients were female (90%).…”

mentioning

confidence: 99%